Has Alan Kramer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $226 in general payments to Alan Kramer, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Kramer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Kramer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Kramer, MD

Cardiovascular Disease · Voorhees, NJNPI 1316918956

Payments from drug & device makers

$226in general payments, 2019–2025

Across 8 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Atricure, Inc.$107
Boston Scientific$49
Amgen$41
Genentech USA, Inc.$29

What the payments were for

Food & beverage$226100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Atricure, Inc.	2	$107
Boston Scientific	2	$49
Amgen	3	$41
Genentech USA, Inc.	1	$29

How this compares

$226 in reported general payments places this provider in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024

$332,891

Medicare patients

1,344

Services billed

4,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	378	$560,619
XareltoRivaroxaban	136	$167,963
Repatha SureclickEvolocumab	193	$158,484
EntrestoSacubitril/Valsartan	72	$107,270
Praluent PenAlirocumab	79	$51,321
Repatha SyringeEvolocumab	45	$41,689
VascepaIcosapent Ethyl	50	$41,623
Atorvastatin Calcium	1,533	$18,661
Ezetimibe	621	$17,876
Icosapent Ethyl	29	$17,035
Rosuvastatin Calcium	954	$16,864
Metoprolol Succinate	984	$14,506
Losartan Potassium	806	$9,463
Amlodipine Besylate	1,149	$9,150
Potassium Chloride	264	$5,757

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Voorhees

Elias IliadisVoorhees$290K
Joseph ParrilloVoorhees$209K
Richard PerlmanVoorhees$183K
Robert KippermanMorristown$5.3M
Sharan MahalBridgewater$3.5M
Linda GillamMorristown$2.2M
Mark GelerntHaddon Heights$2M
Robert FishbergSpringfield$1.9M
Dilip ViswanathHaddon Heights$1.8M
Marc CohenNewark$1M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →